Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Cardiotoxicity × Clear all

Phase

Phase NA 48 Phase 2 18 Phase 3 16 Phase 4 6 Phase 1/2 4 Phase 1 2 Phase EARLY_PHASE1 1 Phase 2/3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 90 Neoplasms 88 Carcinoma, Non-Small-Cell Lung 67 Prostatic Neoplasms 61 Colorectal Neoplasms 59 Carcinoma, Hepatocellular 56 Leukemia, Myeloid, Acute 50 Neoplasm Metastasis 45 Stomach Neoplasms 43 Precursor Cell Lymphoblastic Leukemia-Lymphoma 39 Lung Neoplasms 38 Pancreatic Neoplasms 32 Recurrence 30 Multiple Myeloma 27 Rectal Neoplasms 25 Colonic Neoplasms 24 Leukemia 23 Head and Neck Neoplasms 23 Ovarian Neoplasms 21 Lymphoma 21 Squamous Cell Carcinoma of Head and Neck 20 Hematologic Neoplasms 19 Esophageal Neoplasms 18 Polycystic Ovary Syndrome 17 Myelodysplastic Syndromes 17 Urinary Bladder Neoplasms 16 Melanoma 15 Lymphoma, Large B-Cell, Diffuse 15 Liver Neoplasms 15 Glioblastoma 15

Interventions

Trimetazidine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡